The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 14, 2021

Filed:

Nov. 22, 2019
Applicant:

Takeda Vaccines, Inc., Cambridge, MA (US);

Inventors:

Dan Stinchcomb, Fort Collins, CO (US);

Jorge E. Osorio, Mount Horeb, WI (US);

O'Neil Wiggan, Fort Collins, CA;

Assignee:

Takeda Vaccines, Inc., Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); C12N 7/00 (2006.01); A61K 47/26 (2006.01); C08L 71/02 (2006.01); A61K 47/36 (2006.01); A61K 47/42 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01); A61K 47/42 (2013.01); C08L 71/02 (2013.01); C12N 7/00 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/70 (2013.01); C08G 2650/58 (2013.01); C08L 2203/02 (2013.01); C12N 2710/10051 (2013.01); C12N 2710/10061 (2013.01); C12N 2710/24151 (2013.01); C12N 2710/24161 (2013.01); C12N 2760/16051 (2013.01); C12N 2760/16061 (2013.01); C12N 2760/18411 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24151 (2013.01); C12N 2770/24161 (2013.01); C12N 2770/36151 (2013.01); C12N 2770/36161 (2013.01); Y02A 50/30 (2018.01);
Abstract

Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.


Find Patent Forward Citations

Loading…